Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bydureon in adults with Prader-Willi syndrome
ACTRN12616000710426Phase 3Recruiting
- Sponsor
- Garvan Institute of Medical Research
- Start
- Dec 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of exenatide in Prader-Willi syndrome (PWS) (3 arms), sponsored by Garvan Institute of Medical Research. Primary endpoints: Gastrointestinal safety based on gastric emptying, Appetite scores and 1 more. Started Dec 2016; status: recruiting.
02
Drugs
exenatide
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on ACTRN12616000710426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000710426.